What's
New at
Labrix?
DPD
Simple, non-invasive urine test to track your patients' rate of bone loss. Pair this test with hormone and adrenal panels.
Learn more here.
DNA
FindWhyTM Weight Control Panel for Genetic Tendencies. DNA sample is collected from a non-invasive cheek swab.
Learn more here.
DHT
Acne, hair loss or hirsutism a concern for your patients? Consider adding (DHT)
testing to their saliva test.
Coming soon!
November 13, 2014
Hormone Balance & Alzheimer's

Every 67 seconds someone in the United States develops Alzheimer's disease (AD). Two thirds of these are women. Though early symptoms are typically difficulty remembering new information, the deposition of beta amyloid plaques and tau protein tangles build inside cells and eventually cause the death of neurons that control memory, personality, and those that regulate basic metabolic processes and physiologic function. Consequently, Alzheimer's disease is now the 6th leading cause of death in the US - responsible for more deaths than prostate and breast cancer combined.

There are many ideas about what contributes to AD including insulin resistance (AD has been referred to as Type 3 diabetes), exposure to toxins and heavy metals, uncontrolled inflammation, food intolerances and changes in neurotransmitter levels. There is a significant decline in the production of a neurotransmitter called acetylcholine with AD patients, and a relationship between this and changes in hormone levels. This may be one of the reasons that the disease disproportionately affects women. Estrogen stimulates the synthesis of acetylcholine and increases the number of synapses in the hippocampus, a part of the brain that is integral to memory storage. Additionally, estrogen protects the brain from oxidative stress, amyloid B peptide and glutamate induce toxicity. In fact, estrogen replacement has been shown to improve memory and cognition in women with Alzheimer's disease and may modulate the risk of developing AD in the first place.

Progesterone is well established as an anti-inflammatory agent in the brain and can increase brain-derived neurotrophic factor (BDNF), an important agent that supports the survival of neurons and encourages the growth of new ones. Progesterone also protects against amyloid B-peptide toxicity, the main component in the amyloid plaques found in the brains of Alzheimer patients.

The restoration of balanced hormones is an integral part of the treatment for Alzheimer's disease and maintaining optimal hormone levels may help to protect against the damage and degeneration that leads to the disease in the first place.

References:
  • http://www.alz.org/alzheimers_disease_facts_and_figures.asp
  • de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes - evidence reviewed. J Diabetes Sci Technol. Nov 2008; 2(6):1101-1113.
  • Hu XY, et al. Decreased estrogen receptor-alpha expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathol. 2003 Sep;106(3):213-20.
  • Sribnick EA, et al. Estrogen attenuates glutamate-induced cell death by inhibiting Ca2+ influx through L-type voltage-gated Ca2+ channels. Brain Res. 2009 Jun 18;1276:159-70. Epub 2009 Apr 21.
  • Gonzales GF, Carillo C. Blood serotonin levels in postmenopausal women: effects of age and serum oestradiol levels. Maturitas. 1993;17:23-9.
  • Brann D, et al. Oestrogen signalling and neuroprotection in cerebral ischaemia. J Neuroendocrinol. 2012 Jan;24(1):34-47.
  • Bartus RT, Dean RL, 3rd, Beer B, Lippa AS 1982 The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414
  • Gabor R, Nagle R, Johnson DA, Gibbs RB. Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus. Brain Res. 2003 Feb 7;962(1-2):244-7.
  • Van Amelsvoort T, Murphy DGM, Robertson D, Daly E, Whitehead M, Abel K. Effects of long-term estrogen replacement therapy on growth hormone response to pyridostigmine in healthy postmenopausal women. Psychoneuroendocrinology. 2003. 28,101-112.
  • Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis. 2011;26(3):495-505.
  • Craig MC, Murphy DG. Estrogen therapy and Alzheimer's dementia. Ann N Y Acad Sci. 2010 Sep;1205:245-53.
  • Labombarda F, et al. Progesterone and the spinal cord: good friends in bad times. Neuroimmunomodulation. 2010;17(3):146-9. Epub 2010 Feb 4.
  • Goodman Y, et al. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996 May;66(5):1836-44..

Labrix Advanced Workshop

Click here for a special invitation to Labrix Advanced Workshop from Labrix co-founder and CEO Dr. Erin Lommen.




Click here to register today!


Labrix Celebrates its 10th Anniversary!

Labrix co-founders Dr. Erin Lommen and Dr. Jay Mead sit down for a short interview and discuss the company's first ten years, as well as its bright future with diagnostic testing.




Labrix
Advanced Workshop
Las Vegas, NV
Jan 24-25, 2015

Registration is just $199 for Labrix Advanced Workshop (LAW). Register for LAW today.


Labrix
Core Training
Atlanta, GA
March 14, 2015

Registration is $150 and upon completing this one day training, you will receive a $100 credit on your testing account. Register for Atlanta Core Training today.

A4M
Las Vegas, NV
Dec. 11-13, 2014

Labrix' co-founder Dr. Lommen will be speaking at A4M.

Dr. Erin Lommen will be speaking on Metabolic Syndrome and Menopause.